Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2021-04-23 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
中源协和细胞基因工程股份有限公司董事会审计委员会2020年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "Board of Directors Audit Committee 2020 Annual Performance Report" of a company. It details the activities, meetings, and evaluations conducted by the audit committee during the 2020 fiscal year, including oversight of external auditors, internal audit work, internal control evaluations, and communication with management and auditors. The content focuses on the audit committee's duties and their fulfillment over the year, rather than presenting the full audited financial statements or the complete annual report. The document is a report on the audit committee's work and oversight, which fits the definition of an Audit Report / Information (AR) filing, as it is a standalone audit-related report and not the full Annual Report (10-K). The document length is 2490 characters, which is relatively short but contains substantive audit committee information rather than just an announcement or certification. Therefore, the appropriate classification is AR with high confidence.
2021-04-23 Chinese
中源协和细胞基因工程股份有限公司关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about a change in accounting policy related to the adoption of a new lease accounting standard effective from January 1, 2021. It details the impact of this change on the company's financial statements as of that date, including adjustments to assets and liabilities. The document includes opinions from independent directors and the supervisory board confirming the legitimacy and compliance of the change. The document is relatively short (2251 characters) and focuses on the accounting policy change and its financial impact, but it is not a full financial report like an annual or interim report. It is not a certification or a simple announcement of a report being published. It is a regulatory announcement about accounting policy change, which fits best under Regulatory Filings (RNS) as it does not constitute a full audit report or annual report, nor is it a management report or earnings release. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-04-23 Chinese
中源协和细胞基因工程股份有限公司独立董事关于重组整合的独立意见
Audit Report / Information Classification · 85% confidence The document is an independent opinion from independent directors regarding the integration of a merger target company, referencing governance guidelines and a special audit report on performance commitments. It discusses the merger integration and performance verification but does not contain full financial statements or detailed financial results. It is a standalone opinion related to a merger and audit findings, not a full annual report or audit report by itself. Given the focus on merger integration and independent directors' opinion, it aligns best with Audit Report / Information (AR) as it includes a special audit report reference and independent directors' opinion on the merger integration.
2021-04-23 Chinese
中源协和细胞基因工程股份有限公司2020年年度报告
Annual Report Classification · 100% confidence The document is titled "2020 年年度报告" which translates to "2020 Annual Report". It contains detailed financial data, company business overview, management statements, audit opinions, and comprehensive financial statements. The length is about 15,000 characters, indicating a full report rather than a brief announcement. It includes audited financial results, risk disclosures, business segments, and governance information typical of an annual report. The presence of an audit report within the document does not make it a standalone audit report but part of the annual report. Therefore, the document fits the definition of an Annual Report (10-K).
2021-04-23 Chinese
中源协和细胞基因工程股份有限公司关于召开2020年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2020 Annual General Meeting (AGM) of the company, including details such as the date, voting methods, agenda items, and instructions for shareholders. It does not contain the actual annual report or financial statements but rather information about the meeting where such reports will be discussed and voted on. The document length is 3446 characters, which is relatively short and consistent with an announcement or notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2021-04-23 Chinese
中源协和细胞基因工程股份有限公司独立董事关于计提资产减值损失的独立意见
Audit Report / Information Classification · 90% confidence The document is an independent opinion from independent directors regarding the company's decision to recognize asset impairment losses. It references compliance with corporate governance standards and accounting principles but does not contain financial statements or detailed financial data. The document is short (533 characters) and serves as an attestation or certification of the impairment decision rather than a full audit or annual report. Therefore, it fits best under Audit Report / Information (AR), as it relates to audit-related opinions on accounting treatments but is not a full annual report or interim report.
2021-04-23 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.